Legend Biotech Corporation Total Debt to Total Equity
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
| Total Debt to Total Equity | 0.0x | 0.5x | (0.0x) | 0.0x | 0.3x | 0.4x | 0.3x |
Legend Biotech Corporation (LEGN) Total Debt to Total Equity comparison analysis
General
LTM Total Debt to Total Equity
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
LEGN key stats
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
% growth | 23.6 0.0% | 49.1 108.2% | 57.3 16.5% | 75.7 32.2% | 89.8 18.7% | 117.0 30.3% | 285.1 143.7% |
| Cost of Goods Sold (COGS) | (0.1) | 0.0 | 0.0 | 232.2 | 313.3 | 65.4 | 144.2 |
% margin | 23.7 100.4% | 49.1 100.0% | 57.3 100.0% | (156.5) (206.8%) | (223.6) (249.0%) | 51.6 44.1% | 140.9 49.4% |
| Operating Expenses | 9.6 | 64.2 | 192.6 | 304.9 | 462.8 | 509.7 | 140.9 |
| Research & Development Expenses (R&D) | 8.2 | 60.6 | 161.9 | 232.2 | 313.3 | 335.6 | 382.2 |
| Selling, General & Administrative Expenses (SG&A) | 1.4 | 3.9 | 32.4 | 72.7 | 149.5 | 174.0 | 200.9 |
% margin | 13.8 58.4% | (1.5) (3.1%) | (130.9) (228.5%) | (313.3) (414.1%) | (393.0) (437.7%) | (455.8) (389.6%) | (439.5) (154.1%) |
| Interest Income | 0.0 | 6.2 | 4.6 | 2.9 | 1.0 | 8.2 | 54.5 |
| Interest Expense | 0.0 | 0.1 | 0.2 | 4.2 | 0.9 | 10.8 | 21.8 |
| Pre-tax Income | 13.8 | (1.6) | (130.4) | (307.6) | (386.2) | (445.7) | (520.1) |
% effective tax rate | 4.5 32.3% | 1.2 (72.3%) | 2.6 (2.0%) | (4.1) 1.3% | 0.0 (0.0%) | 0.6 (0.1%) | (1.9) 0.4% |
% margin | 9.4 39.7% | (2.8) (5.7%) | (133.0) (232.2%) | (303.5) (401.0%) | (386.2) (430.1%) | (446.3) (381.5%) | (518.3) (181.8%) |
| EPS | 0.07 | (0.03) | (1.01) | (2.57) | (2.74) | (2.81) | (2.94) |
| Diluted EPS | 0.07 | (0.03) | (1.01) | (2.57) | (2.74) | (2.81) | (2.94) |
% margin | 14.1 59.6% | 0.1 0.3% | (124.9) (218.1%) | (294.1) (388.7%) | (392.4) (437.0%) | (416.5) (356.0%) | (477.9) (167.6%) |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Legend Biotech Corporation's Total Debt to Total Equity?
As of today, Microsoft Corp's last 12-month Total Debt to Total Equity is 0.3x, based on the financial report for Sep 30, 2024 (Q3’2024). The average annual Total Debt to Total Equity for Legend Biotech Corporation have been 0.3x over the past three years, and 0.2x over the past five years.
2) Is Legend Biotech Corporation's Total Debt to Total Equity Good?
As of today, Legend Biotech Corporation's Total Debt to Total Equity is 0.3x, which is higher than industry median of 0.0x. It indicates that Legend Biotech Corporation's Total Debt to Total Equity is Bad.